Cullinan Oncology (NASDAQ:CGEM – Get Rating) and Aptose Biosciences (NASDAQ:APTO – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
Earnings & Valuation
This table compares Cullinan Oncology and Aptose Biosciences' revenue, earnings per share and valuation.
Get
Cullinan Oncology alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Cullinan Oncology | $18.94 million | 29.52 | -$65.57 million | $2.22 | 5.52 |
| Aptose Biosciences | N/A | N/A | -$65.35 million | ($0.61) | -1.09 |
Aptose Biosciences has lower revenue, but higher earnings than Cullinan Oncology. Aptose Biosciences is trading at a lower price-to-earnings ratio than Cullinan Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cullinan Oncology and Aptose Biosciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Cullinan Oncology | N/A | -33.66% | -31.74% |
| Aptose Biosciences | N/A | -92.87% | -81.08% |
Risk & Volatility
Cullinan Oncology has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Cullinan Oncology and Aptose Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Cullinan Oncology | 0 | 0 | 3 | 0 | 3.00 |
| Aptose Biosciences | 0 | 0 | 4 | 0 | 3.00 |
Cullinan Oncology presently has a consensus target price of $50.00, indicating a potential upside of 307.83%. Aptose Biosciences has a consensus target price of $7.75, indicating a potential upside of 1,062.09%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Cullinan Oncology.
Institutional & Insider Ownership
82.5% of Cullinan Oncology shares are held by institutional investors. Comparatively, 27.2% of Aptose Biosciences shares are held by institutional investors. 7.5% of Cullinan Oncology shares are held by company insiders. Comparatively, 10.9% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Cullinan Oncology beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.
About Cullinan Oncology
(Get Rating)
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Aptose Biosciences
(Get Rating)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
